On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update. We anticipate data from the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, before the end of 2025. This cohort was added to evaluate the non-titrated maximum tolerated dose of DA-1726. Next steps in that program will depend on the efficacy and safety outcomes of that cohort. In addition, MetaVia is working to schedule an 'End-of-Phase 2' meeting with the FDA regarding next steps for DA-1241, an oral GPR119 agonist being developed for the treatment of MASH. The company is actively looking to out-license the compound or find a development partner before advancing it further in the clinic.
